Skip to main content
Full access
Commentaries
Published Online: 1 June 2016

The RDoC Controversy: Alternate Paradigm or Dominant Paradigm?

The National Institute of Mental Health’s (NIMH) Research Domain Criteria (RDoC) initiative is controversial within psychiatry and within the research community. Much has been written on this subject (13). Here I comment on two vexing issues: RDoC versus DSM-5 and whether NIMH is stepping back from clinically relevant research.

RDoC Versus DSM-5

While DSM and ICD are diagnostic manuals, RDoC is not. What RDoC is, instead, is a set of principles for deriving and studying biobehavioral constructs implicated in psychiatric disorders. Current diagnostic categories are valid for many purposes and represent the best effort to relate science to nosology. There is no better alternative at present for clinical application. However, there are very significant limitations in the scientific application of heterogeneous syndromes where the defining psychopathologies are not unique to the diagnostic class and vary within categories between cases. Consider the limitations of schizophrenia as the phenotype in genome-wide association studies, where individuals in a study cohort differ on virtually every clinical variable. Hence, results from such studies yield mostly weak findings with unknown relation to specific pathology and false negative exclusion of genes based on failure to apply robust phenotypes to select relevant individuals.
RDoC provides one of several paradigms addressing syndrome heterogeneity. DSM-5 provides eight symptom dimensions for psychotic disorders in section 3. These psychopathology domains require clinical attention and are targets for research. Translational research involving animals is used to generate knowledge hypothesized to relate to specific pathologies relevant to diagnostic class but not to represent the range of pathologies associated with the class. The Consortium on the Genetics of Schizophrenia (4, 5) and the Bipolar-Schizophrenia Network on Intermediate Phenotypes (6) endophenotype programs are outstanding examples of the deconstruction of clinical syndromes.
Science resulting in advances in clinical care has been modest. In this context, NIMH gave emphasis to RDoC as a paradigm with the hypothesis that research based on already defined behavioral constructs with known neural circuits will accelerate the development of fundamental knowledge applicable to psychopathology while reducing problems associated with heterogeneous clinical syndromes. The RDoC initiative neither replaces nor excludes other paradigms, but it is an NIMH strategic plan priority and competes for resources. In this regard it will eventually be judged by whether knowledge generated within this paradigm is validated in relation to human pathology and whether clinically relevant innovations are produced.
The issue is not whether RDoC is an alternative diagnostic approach but whether the paradigm will promote information that informs nosology and facilitates application of brain science in clinical diagnostic concepts. In addition to freeing investigators from the approach of diagnostic class versus normal control, possible outcomes relevant to DSM and ICD are that:
Psychopathology spectra may be identified that optimize the grouping of diagnostic classes;
Porous boundaries between diagnostic classes may be clarified, with implications for classification or diagnostic criteria;
Fundamental aspects of psychopathology may be identified, and comorbid conditions may be viewed between specific pathologies rather than between heterogeneous clinical syndromes;
Integration of brain science with diagnoses may be facilitated; and
Novel concepts regarding the organization of mental disorders may emerge.
In the above examples, new information from RDoC and from other sources would be used to revise classification (think DSM-5.1, DSM-5.2, etc.), and brain science may be more closely related to clinical constructs over the long term. Of immediate interest is whether RDoC-generated knowledge will identify novel targets for therapeutic and prevention discovery. The current RDoC model can be viewed at https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml and includes self-reports to facilitate translation to clinically assessed psychopathology.

RDoC and Clinical Relevance

In the context of frustration with the slow pace of advancing knowledge on major mental disorders, there is a concern that NIMH is moving away from clinical trials and psychopathology research in favor of more basic science. RDoC may be misunderstood in this regard. What the RDoC paradigm endeavors to do is to alert investigators to the fallacy of methods that equate diagnosis with a specific disease (7). Investigators are encouraged to address psychopathology in the context of hypothesized neural circuits and behavioral constructs with the freedom, but not the requirement, to work across diagnostic boundaries. It is hoped that selected behavioral constructs will increase the validity of mapping phenotypes from human to rodent and that exploring cellular and molecular mechanisms will be more informative when related to specific neural circuits and behavioral constructs. RDoC principles also include the view that psychopathology is dimensional and that a sharp line dividing pathology and normalcy is often not present. Studies embracing these principles have been conducted before the RDoC initiative and presently both within and apart from the formal RDoC initiative. The categorical methods common when contrasting normal volunteers with a diagnosis cohort or between diagnostic cohorts are outside the RDoC framework but are not excluded from NIMH support. However, if heterogeneity undermines hypothesis testing, it needs to be addressed. Confusion early in the RDoC initiative at the application and review stages has created misunderstandings in this regard and has contributed to negativity in the field.
The NIMH strategic plan calls for psychopathology more informed by brain science. RDoC is a tactical approach. It is not intended to increase basic science and decrease clinical science. Rather, the hypothesis is that translational research will be enhanced and that clinically relevant knowledge will be accelerated. It is too early to determine the effectiveness of the program, and it is good for the field to debate the best paradigms for advancing knowledge. But RDoC is compatible with the public health mission of NIMH and is motivated by the limited success of traditional paradigms.
RDoC is not intended to be a comprehensive approach to all the several hundred diagnostic categories described in DSM-5. The chapter on Schizophrenia Spectrum and Other Psychotic Disorders gives emphasis to the five symptom criteria for schizophrenia and additional dimensions on depression, mania, and cognition. The five RDoC domains are substantially relevant to cognition, depression, and negative symptoms but are less developed in relation to reality distortion, thought pathology observed in speech, and psychomotor abnormalities. Examining dimensions across diagnoses may identify critical similarities or differences between schizophrenia and bipolar disorder (8), for example. RDoC is a work in progress, and methods with relevance for these pathology dimensions may be addressed within the five RDoC domains or by establishing further domains (911).

References

1.
Maj M: Keeping an open attitude towards the RDoC project. World Psychiatry 2014; 13:1–3
2.
Weinberger DR, Glick ID, Klein DF: Whither Research Domain Criteria (RDoC)? the good, the bad, and the ugly. JAMA Psychiatry 2015; 72:1161–1162
3.
Yee CM, Javitt DC, Miller GA: Replacing DSM categorical analyses with dimensional analyses in psychiatry research: the Research Domain Criteria initiative. JAMA Psychiatry 2015; 72:1159–1160
4.
Calkins ME, Dobie DJ, Cadenhead KS, et al: The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull 2007; 33:33–48
5.
Seidman LJ, Hellemann G, Nuechterlein KH, et al: Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res 2015; 163:73–79
6.
Clementz BA, Sweeney JA, Hamm JP, et al: Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry 2016; 173:373–384
7.
Cuthbert BN, Insel TR: Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 2013; 11:126–133
8.
Cuthbert BN, Insel TR: Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull 2010; 36:1061–1062
9.
Ford JM, Morris SE, Hoffman RE, et al: Studying hallucinations within the NIMH RDoC framework. Schizophr Bull 2014; 40(Suppl 4):S295–S304
10.
Badcock JC, Hugdahl K: A synthesis of evidence on inhibitory control and auditory hallucinations based on the Research Domain Criteria (RDoC) framework. Front Hum Neurosci 2014; 8:180
11.
Waters F, Allen P, Aleman A, et al: Auditory hallucinations in schizophrenia and nonschizophrenia populations: a review and integrated model of cognitive mechanisms. Schizophr Bull 2012; 38:683–693

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 562 - 563
PubMed: 27245188

History

Accepted: March 2016
Published online: 1 June 2016
Published in print: June 01, 2016

Authors

Details

William T. Carpenter, Jr., M.D.
From the Department of Psychiatry and the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore.

Notes

Address correspondence to Dr. Carpenter ([email protected]).

Funding Information

National Institute of Mental Health10.13039/100000025: 1P50MH082999
Dr. Carpenter chaired the DSM-5 Psychotic Disorders Work Group and was a member of the DSM-5 Task Force and the Study Group on Diagnostic Spectra; he served as DSM-5 liaison with the NIMH Research Domain Criteria Unit and later as an external adviser; he is supported by NIMH to consult on selected issues, including those discussed in this commentary; and he has received support from Genentech, HealthAnalytics, PharmaGenesis, and Teva.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share